Anti-Tumor Necrosis Factor-α Induced Systemic Lupus Erythematosus

Open Rheumatology Journal

Volumn 6, Issue 1, 2012, Pages 315-319

  Almoallim, Hani ^a   Al Ghamdi, Yahya ^a   Almaghrabi, Haneen ^a   Alyasi, Omnia ^a  

^a UMM AL QURA UNIVERSITY   (Saudi Arabia)

Author keywords

Anti tumour necrosis factor alpha; Disease modifying anti rheumatic drugs; Drug induced lupus; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; HERMES ANTIGEN; HISTONE ANTIBODY; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 10; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; PHOSPHOLIPID ANTIBODY; PROCAINAMIDE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIBODY PRODUCTION; CLINICAL FEATURE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INCIDENCE; LABORATORY DIAGNOSIS; LUPUS LIKE SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84870983776     PISSN: None     EISSN: 18743129     Source Type: Journal    
DOI: 10.2174/1874312901206010315     Document Type: Review

References (28)

1. Danese S. Adalimumab in ulcerative colitis: Ready for prime time. Dig Liver Dis 2012. [In Press].
2. Vasoo S. Drug-induced lupus: an update. Lupus 2006; 15(11): 757-61.
3. Haraoui B, Keystone E. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr Opin Rheumatol 2006; 18(1): 96-100.
4. van Rijthoven AW, Bijlsma JW, Canninga-van Dijk M, Derksen RH, van Roon JA. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level. Rheumatology 2006; 45(10): 1317-9.
5. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86(4): 242-51.
6. Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford) 2009; 48(7): 716-20.
7. Gonnet-Gracia C, Barnetche T, Richez C, Blanco P, Dehais J, Schaeverbeke T. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. Clin Exp Rheumatol 2008; 26(3): 401-7.
8. Singh VK, Mehrotra S, Agarwal SS. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res 1999; 20(2): 147-61.
9. Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis 1999; 5(4): 285-94.
10. Maczynska I, Millo B, Ratajczak-Stefanska V, et al. Proinflammatory cytokine (IL-1beta, IL-6, IL-12, IL-18 and TNFalpha) levels in sera of patients with subacute cutaneous lupus erythematosus (SCLE). Immunol Lett 2006; 102(1): 79-82.
11. Kang MJ, Lee YH, Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci 2006; 21(5): 946-9.
12. Cairns AP, Duncan MK, Hinder AE, Taggart AJ. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 2002; 61(11): 1031-2.
13. Hart SP, Dougherty GJ, Haslett C, Dransfield I. CD44 regulates phagocytosis of apoptotic neutrophil granulocytes, but not apoptotic lymphocytes, by human macrophages. J Immunol 1997; 159(2): 919-25.
14. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 2005; 64(3): 403-7.
15. Bickerstaff MC, Botto M, Hutchinson WL, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999; 5(6): 694-7.
16. Lorenz HM, Herrmann M, Winkler T, Gaipl U, Kalden JR. Role of apoptosis in autoimmunity. Apoptosis 2000; 5(5): 443-9.
17. Sarzi-Puttini P, Atzeni F, Capsoni F, Lubrano E, Doria A. Druginduced lupus erythematosus. Autoimmunity 2005; 38(7): 507-18.
18. Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008; 37(6): 381-7.
19. De Bandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005; 7(3): R545-51.
20. Katz U, Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev 2010; 10(1): 46-50.
21. Cambien B, Bergmeier W, Saffaripour S, Mitchell HA, Wagner DD. Antithrombotic activity of TNF-alpha. J Clin Invest 2003; 112(10): 1589-96.
22. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65(7): 889-94.
23. Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol 2011; 50(5): 619-25.
24. Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008; 22(5): 847-61. Review.
25. Wetter DA, Davis MD. Lupus-like syndrome attributable to antitumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009; 84(11): 979-84.
26. Almoallim H, Almasari A, Khadawardi H. Lupus Myositis with Normal Creatinine Kinase Levels Following Adalimumab Use in a Rheumatoid Arthritis Patient. Turk J Rheumatol 2011; 26(4): 328-32
27. Cush JJ. Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus. Clin Exp Rheumatol 2004; 22(5 Suppl 35): S141-7.
28. Papagoras C, Voulgari PV, Drosos AA. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. Autoimmun Rev 2010; 9(8): 574-82.